ArticleRespiratory research2026
COPD in China: the analysis of mortality and burden of disease trends from 2008 to 2021.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTo determine basic death situation and assess trends in disease burden, we analyzed the death information of Chronic Obstructive Pulmonary Disease (COPD) among Chinese residents from 2008 to 2021.
methodsData were collected from the Cause-of-Death Surveillance dataset in China. The Crude Mortality Rate (CMR), Age-Standardized Mortality Rate (ASMR), Potential Years of Life Lost (PYLL), and Potential Years of Life Lost Rate (PYLLR) of COPD among Chinese residents from 2008 to 2021 were calculated by Excel 2016. The trends of ASMR and PYLLR were assessed by the average annual percentage change (AAPC), and the difference in mortality was tested by Chi-square tests(χ
resultsThe ASMR of COPD in Chinese residents decreased from 78.84/100,000 in 2008 to 27.81/100,000 in 2021 at an average annual rate of 8.41%, and the PYLLR of COPD in Chinese residents decreased from 1.28‰ in 2008 to 0.53‰ in 2021 at an average annual rate of 6.06%. From 2008 to 2021, the COPD ASMR and PYLLR among Chinese males were higher than females, urban areas were lower than rural areas, western China was higher than central China, and central China was higher than that in eastern China. The decline rate of COPD ASMR and PYLLR was significantly higher in females than males, rural areas than urban areas, and eastern/central regions than western regions.
conclusionsThe mortality and disease burdens of COPD in China decreased yearly and were higher in the elderly, males, rural areas, and western China. The disease burden of COPD decreased more rapidly in women, rural areas, eastern and central China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.